https://www.selleckchem.com/products/rbn-2397.html
No significant associations were noted for neurologic outcomes, anaphylaxis, or cardiac events. No major safety problems were detected following the first or second dose of the vaccine to prevent COVID-19 in the study cohort from December 18, 2020 through March 7, 2021. No major safety problems were detected following the first or second dose of the vaccine to prevent COVID-19 in the study cohort from December 18, 2020 through March 7, 2021.To improve the safety of genetically modified live rabies vaccine strains, most studies have uti
Like
Comment
Share
